Key facts
- This page summarizes Melissa B. Epperly's Form 4 filing for Zentalis Pharmaceuticals, Inc. (ZNTL).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 Feb 2024, 20:22.
Melissa B. Epperly - 12 Feb 2024 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ZNTL
- Reported as of
- 12 Feb 2024
- Net transaction value
- -$29,435
- SEC form
- 4
- Accepted by SEC
- 12 Feb 2024, 20:22:44 UTC
- Prior SEC filing
- 05 Feb 2024
- Next SEC filing
- 05 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Melissa B. Epperly
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Melissa B. Epperly filed Form 4 for Zentalis Pharmaceuticals, Inc. (ZNTL) on 12 Feb 2024.
Change
- Previous filing in this sequence was filed on 05 Feb 2024.
- Current net transaction value: -$29,435.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZNTL
transaction
Common Stock
Sale
- Transaction value
- $29,435
- Shares
- -2,573
- Change %
- -0.57%
- Price
- $11.44
- Shares after
- 451,449
- Date
- 12 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person.
Footnote F2
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.